Just yesterday, the FDA sent out a warning that the anti-seizure medication clobazam (Onfi) can cause serious skin reactions. There have been reported cases of Stevens-Johnson’s syndrome (SJS) and toxic epidermal necrolysis (TEN) that have resulted in hospitalization, blindness and death. The likelihood of skin reactions is greater during the first 8 weeks of treatment or when the drug is stopped and then re-started, however it can occur anytime. The FDA has approved labeling and patient Medication Guide changes to include warnings of these skin reactions. Have you subscribed to the FDA safety alerts to keep up-to-date with medication safety? Have any of your patients described skin reactions with clobazam?
For more information, please click here.